Posted by Michael Wonder on 14 Dec 2024
Roche Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Tecentriq SC (atezolizumab solution for subcutaneous injection)
13 December 2024 - Roche Canada today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Tecentriq SC (atezolizumab) on 19 November 2024.
The pan-Canadian Pharmaceutical Alliance negotiates on behalf of the provinces and territories, making the end of these negotiations a critical step in bringing TECENTRIQ SC closer to public access.
